Welcome to our dedicated page for Galectin Therapeutics news (Ticker: GALT), a resource for investors and traders seeking the latest updates and insights on Galectin Therapeutics stock.
Galectin Therapeutics Inc (NASDAQ: GALT) pioneers novel carbohydrate-based therapies targeting galectin-3 proteins to address fibrotic diseases and cancers. This page serves as the definitive source for verified company announcements, including clinical trial milestones, regulatory updates, and strategic partnerships.
Investors and researchers will discover timely updates on adaptive clinical programs for conditions like MASH cirrhosis, oncology developments, and scientific advancements in galectin inhibition technology. All content is curated to provide actionable insights without speculative commentary.
The repository includes earnings reports, FDA communications, research collaborations, and therapeutic pipeline progress. Bookmark this page for streamlined access to GALT's latest developments in carbohydrate-based drug innovation and fibrotic disease research.
Galectin Therapeutics Inc. (NASDAQ: GALT) announced its participation in the H.C. Wainwright BioConnect Investment Conference on May 2, 2023. CEO Joel Lewis and CMO Dr. Pol F. Boudes will engage in a discussion about the NAVIGATE trial targeting NASH cirrhosis. A live webcast of the event will be available at 10:30 a.m. ET. Belapectin, the company's lead drug, targets galectin-3 and shows promise in reversing liver fibrosis. The NAVIGATE trial, evaluating belapectin's efficacy in preventing esophageal varices in NASH cirrhosis, has completed randomization with results expected in Q4 2024. NASH, affecting up to 28 million U.S. citizens, can lead to cirrhosis, where liver transplants are often the only treatment. The company aims to develop new therapies for chronic liver diseases and cancer.
Galectin Therapeutics, Inc. (NASDAQ: GALT) attended the 2023 Emerging Topic Conference on NASH Cirrhosis, organized by the American Association for the Study of Liver Diseases (AASLD) in Los Angeles on March 25-26, 2023. The conference targeted NASH cirrhosis, emphasizing its growing global health concern and the limitations of current treatment options, primarily liver transplantation. Galectin's NAVIGATE study is under review, focusing on the prevention of esophageal varices using belapectin, a galectin-3 inhibitor aimed at non-alcoholic steatohepatitis (NASH) patients. The conference discussed the critical role of liver macrophages and the challenges of using liver biopsies for diagnosing cirrhosis. Dr. Pol Boudes, Chief Medical Officer, highlighted the urgency of addressing NASH cirrhosis, with projections indicating a potential crisis in liver transplant availability in the U.S.
FAQ
What is the current stock price of Galectin Therapeutics (GALT)?
What is the market cap of Galectin Therapeutics (GALT)?
